Medicine Requirements and Budget Implication for Pediatric Acute Lymphoblastic Leukemia in Indonesia: A Morbidity-Based Approach Authors: Dita N S Argadiredja, Mohammed Alfaqeeh, Yasmin Fatinah, Vesara Ardhe Gatera, Lucia R Andalusia, Rano K Sinuraya, Dina Abushanab, Rizky Abdulah, Auliya A Suwantika Published: 2026 ABSTRACT AbstractBackgroundLimited availability, high costs, and reliance on imported medicines challenge access to pediatric cancer treatment in Indonesia. For childhood acute lymphoblastic leukemia (ALL), the absence of reliable national quantification data complicates procurement, reimbursement, and budget planning. This study estimated hospital-level and national pharmaceutical requirements for pediatric ALL in Indonesia using a morbidity-based forecasting approach.MethodsA budget impact modeling approach using a morbidity-based pharmaceutical quantification framework was developed to estimate theoretical annual procurement requirements for pediatric ALL. Data were derived from three national cancer referral hospitals during the study reference period (January 2022–October 2023) and supplemented with registry data and national treatment guidelines. Drug quantities were calculated using standardized regimens for standard-risk and high-risk patients, assuming an average body weight of 24 kg and body surface area of 0.8 m2. National estimates were extrapolated using disease incidence and risk-group distribution rather than comprehensive national medicine-utilization data. Drug prices were obtained from the national electronic procurement catalogue. The model assumed full completion of standardized treatment regimens without treatment interruptions or dose modifications.ResultsPharmaceutical requirements and expenditure were highly concentrated in a limited number of medicines. The estimated annual national pharmaceutical expenditure was IDR 1.43 billion for standard-risk patients and IDR 4.48 billion for high-risk patients, with a combined budget of IDR 5.91 billion. L-asparaginase accounted for the largest share of expenditure, with annual national costs of IDR 993.3 million for standard-risk patients and IDR 2,885.2 million for high-risk patients. Vincristine and daunorubicin were additional major contributors. Across both risk groups, induction therapy represented the most resource-intensive treatment phase, and the ten highest-cost drug–risk group combinations accounted for approximately 97.8% of total pharmaceutical spending.ConclusionThis study provides the first national morbidity-based estimation of pediatric ALL pharmaceutical requirements and budget implications in Indonesia. The findings highlight key cost drivers and support regimen- and risk-specific forecasting for procurement planning and policy decision-making.Keywords: pediatric acute lymphoblastic leukemia, morbidity-based forecasting, pharmaceutical procurement, budget impact analysis, Indonesia Introduction Childhood cancer remains a major global health challenge, with approximately 400,000 children diagnosed each year worldwide.1 Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and represents a substantial cause of cancer-related morbidity and mortality, particularly in low- and middle-income countries (LMICs).2 While survival rates for pediatric ALL exceed 85% in high-income settings, outcomes in LMICs remain markedly lower, largely due to delayed diagnosis, limited access to treatment, and interruptions in essential medicine supply.3 In Indonesia, pediatric ALL accounts for the largest proportion of childhood cancers, with a pooled incidence estimate of 4.32 cases per 100,000 children, although substantial uncertainty in national incidence estimates remains.4,5 Although national treatment guidelines and the National Health Insurance system (Jaminan Kesehatan Nasional, JKN) are in place, gaps persist in the availability, affordability, and continuity of essential pediatric oncology medicines.6 Pediatric ALL care is concentrated in referral hospitals with pediatric oncology capacity, making continuity of treatment dependent on both referral access and reliable medicine supply.7 Several key drugs used in ALL treatment are imported, making the supply chain vulnerable to procurement delays, price fluctuations, and stock shortages.8 These challenges highlight the importance of reliable pharmaceutical planning to support uninterrupted treatment and equitable access to care.9 Pediatric ALL treatment is structured into sequential phases and stratified according to disease risk, resulting in different medicine requirements across treatment courses.10 Under the national protocol applied in this study, standard-risk treatment comprises induction, consolidation, and maintenance, whereas high-risk treatment additionally includes a re-induction phase.11 Because treatment intensity, duration, and medicine exposure vary by phase and risk group, these characteristics are important determinants of pharmaceutical requirements and therefore key inputs for morbidity-based forecasting.12 Pharmaceutical quantification is a critical component of health system planning and procurement.13 Accurate estimates of drug requirements allow policymakers and procurement agencies to allocate budgets efficiently, prevent stock-outs, and ensure alignment between clinical guidelines and medicine availability.14 Two main approaches are commonly used to estimate pharmaceutical needs: consumption-based and morbidity-based methods.15,16 Consumption-based quantification projects future requirements from historical medicine use and is most informative when reliable utilization data reflect adequately supplied services.17 In contrast, morbidity-based quantification derives requirements from the expected number of patients, disease patterns, standard treatment regimens, and medicine quantities required per treatment course.18 The choice between these approaches depends largely on the availability and reliability of consumption, morbidity, and treatment-protocol data.19 For pediatric ALL in Indonesia, historical consumption may not fully represent underlying pharmaceutical need when medicine availability, treatment access, or supply interruptions constrain observed utilization.20 A morbidity-based approach is therefore appropriate because requirements can be estimated from disease burden, risk-group distribution, standardized treatment protocols, patient characteristics, and medicine dosing rather than relying exclusively on previous consumption. This approach has also been applied to forecasting medicine requirements and costs in pediatric ALL, where incidence, risk stratification, regimen selection, dosing, and pricing constitute key forecasting inputs.21 Despite the high burden of pediatric ALL in Indonesia, national-level pharmaceutical forecasting studies for this disease are lacking.22,23 Existing studies have primarily focused on clinical outcomes,24,25 epidemiology,5 or individual hospital experiences,23 with limited attention to systematic estimation of drug needs across treatment regimens and risk groups. The absence of such data constrains evidence-based procurement planning and limits the ability of policymakers to anticipate budgetary requirements for pediatric cancer care. To address this gap, this study aims to estimate hospital-level and national pharmaceutical requirements for pediatric ALL in Indonesia using a morbidity-based forecasting approach. By integrating registry data, hospital treatment patterns, national clinical guidelines, and procurement prices, this study provides a structured estimation of drug quantities and budget implications for standard-risk and high-risk pediatric ALL patients. The findings are intended to support pharmaceutical procurement planning and inform policy decision-making for pediatric oncology care in resource-limited settings. Methods Study Design and Analytical Approach This study applied a budget impact modeling approach using a morbidity-based pharmaceutical quantification framework to estimate hospital-level and national pharmaceutical requirements for pediatric ALL in Indonesia. The morbidity-based method estimates medicine needs based on disease incidence, treatment protocols, and patient characteristics, and is particularly appropriate in settings where consumption data may be incomplete or influenced by access constraints. Study Setting and Data Sources The analysis used data during the period (2022–2023) from three national cancer referral hospitals in Indonesia: Hasan Sadikin Hospital (Bandung), Cipto Mangunkusumo Hospital (Jakarta), and Dharmais National Cancer Hospital (Jakarta). These hospitals were selected because they serve as major referral centers for pediatric oncology and provide standardized ALL treatment in accordance with national clinical guidelines. Hospital data were supplemented with information from the Indonesian Pediatric Cancer Registry (IP-CAR) to inform estimates of disease incidence and risk-group distribution.26 National clinical guidelines for pediatric ALL treatment were used to define standard treatment regimens and dosing schedules.27 Drug price data were obtained from the national electronic procurement catalogue to reflect current procurement costs in the public health system.28 Treatment Regimens and Risk Stratification Pediatric ALL patients were classified into standard-risk and high-risk groups based on national treatment guidelines.27 For standard-risk patients, three treatment phases were considered: induction, consolidation, and maintenance. For high-risk patients, four treatment phases were included: induction, consolidation, re-induction, and maintenance. Each treatment phase was defined by a standardized combination of medicines, dosing schedules, and number of cycles as specified in the national pediatric ALL protocol. Only medicines listed in the national formulary and routinely used in public hospitals were included in the analysis. Assumptions and Patient Characteristics Drug quantity calculations were based on average pediatric patient characteristics derived from hospital records and clinical input from pediatricians involved in pediatric ALL care at the participating hospitals.27 The pediatricians were consulted to assess the clinical appropriateness of these assumptions for use in the forecasting model; this consultation was not conducted as a formal structured validation process. An average body weight of 24 kg and body surface area of 0.8 m2 were assumed for dosing calculations. These values were applied consistently across all treatment phases and risk groups to ensure comparability. Additional assumptions included full completion of treatment regimens as specified in the national protocol, no treatment interruption due to stock-outs or clinical complications, and use of standard dosing without dose escalation or reduction. These assumptions were necessary to estimate theoretical pharmaceutical requirements and reflect an idealized scenario for procurement planning. Estimation of Drug Quantities For each treatment phase and risk group, the total amount of each medicine required per patient was calculated based on dose per cycle, number of cycles, and formulation strength. Protocol doses were first converted into the medicine-specific dosing unit (eg, mg or IU) using the assumed body weight of 24 kg or body surface area of 0.8 m2, where applicable. The resulting dose was multiplied by the scheduled number of administrations and treatment cycles to obtain the total quantity of active ingredient required per patient for each treatment phase. This quantity was then converted into the corresponding dosage-form units (eg, tablets or vials) based on the formulation strength and subsequently into procurement units (packs) according to the pack size used in the national electronic procurement catalogue. Hospital-level procurement requirements were calculated by multiplying the per-patient requirement by the projected number of patients in each risk group and treatment phase. National requirements were subsequently extrapolated using the estimated national pediatric ALL caseload and corresponding risk-group and treatment-phase distributions. Hospital-level treatment-phase distributions were used to inform the treatment-phase proportions applied in the national forecasting model. The national treatment-phase proportions presented in Table 1 represent model inputs used for national extrapolation and should not be interpreted as weighted averages of the treatment-phase percentages observed across the three participating hospitals. The model estimated complete-course pharmaceutical requirements for the projected pediatric ALL patient population rather than annual prevalent treatment-phase demand. Accordingly, medicine requirements across all protocol-defined treatment phases were attributed to the modeled patient cohort for procurement-planning purposes, although completion of the full treatment course may extend beyond a single calendar year. For each medicine, the estimated budget impact was calculated by multiplying the required number of procurement packs by the applicable price per pack. The forecasting model assumed full treatment completion without dose modification, treatment abandonment, death, treatment interruptions due to clinical complications, medicine wastage, or stock-outs. These assumptions represent an idealized procurement-planning scenario for estimating theoretical medicine requirements under standardized protocol-based treatment and should not be interpreted as observed real-world medicine consumption. Table 1Distribution of Pediatric Acute Lymphoblastic Leukemia Patients Across Treatment Regimens by Risk GroupLineRegimenRSHSRSCMRS DharmaisNationalStandard RiskInduction48%47%54%54%Consolidation45%47%30%30%Maintenance7%6%16%16%TOTAL100%100%100%100%High RiskInduction34%38%47%47%Consolidation32%38%26%26%Re-induction30%19%14%14%Maintenance4%5%14%14%TOTAL100%100%100%100%Notes: National treatment-phase percentages represent forecasting-model inputs and are not weighted averages of the three hospital-specific distributions. Distribution of Pediatric Acute Lymphoblastic Leukemia Patients Across Treatment Regimens by Risk Group Notes: National treatment-phase percentages represent forecasting-model inputs and are not weighted averages of the three hospital-specific distributions. Cost Estimation Drug costs were estimated by multiplying required quantities by unit prices obtained from the national electronic procurement catalogue during the study reference period (January 2022–October 2023) and cross-checked against hospital procurement prices from the same period. Costs were expressed in Indonesian Rupiah (IDR). For international comparability, key expenditure estimates were additionally converted to United States dollars (USD) using an approximate reference-period exchange rate of IDR 15,026 per USD 1. USD values were presented as approximate equivalents, while IDR remained the primary currency for the analysis. Budget estimates were calculated at both hospital and national levels and summarized by drug, treatment phase, and risk group. The analysis focused on budget implications for procurement planning and did not aim to assess cost-effectiveness or economic outcomes at the patient level. Data Analysis and Presentation All analyses were conducted descriptively using a structured spreadsheet-based forecasting model developed for this study. Drug requirements were calculated and summarized by treatment phase, risk group, and medicine type. Results were presented as total quantities and corresponding budget estimates at both hospital and national levels. To enhance interpretability for procurement planning, findings were further summarized by identifying the proportional contribution of individual medicines and treatment phases to overall pharmaceutical requirements and expenditure. No statistical hypothesis testing was performed, as the analysis aimed to provide deterministic estimates to support health system planning rather than inferential comparisons. Sensitivity and Scenario Analysis A deterministic one-way sensitivity analysis was performed to assess the robustness of the estimated national pharmaceutical budget to uncertainty in key model inputs. Because empirical parameter distributions or confidence intervals were unavailable, selected inputs were varied individually using predefined scenario bounds while all other model parameters were held at their base-case values. The national pediatric ALL caseload and medicine prices were varied by ±20% from the base case. Body surface area was varied by ±20%, from 0.64 to 0.96 m2 around the base-case value of 0.8 m2. BSA variation was applied only to medicines dosed according to body surface area, whereas fixed-dose medicines were held constant. Additionally, treatment completion was evaluated as a separate scenario. The base-case model assumed 100% completion of the protocol-defined treatment course, while an alternative 80% treatment-course delivery scenario was modeled to examine the effect of incomplete treatment delivery on pharmaceutical requirements and expenditure. This 80% value was used as an analytical scenario rather than an observed treatment-completion estimate for Indonesia. The primary outcome of the sensitivity and scenario analyses was the total estimated national pharmaceutical budget. Results Patient Distribution and Treatment Regimens The morbidity-based forecasting model estimated a total of 957 pediatric ALL patients per year at the national level. At the hospital level, the estimated annual number of pediatric ALL patients was 67 patients at RSHS, 50 patients at RSCM, and 58 patients at Dharmais National Cancer Hospital (Figure 1). Together, these three national referral hospitals represented approximately 18% of the estimated national pediatric ALL caseload and were selected because they are among the principal pediatric oncology centers in Indonesia, using standardized treatment protocols and serving as major referral hubs. Their data were therefore used to inform model assumptions and treatment-pattern inputs for national extrapolation. Nevertheless, the estimates may not fully capture variability in case mix or treatment practices across all hospitals nationwide. At the national level, 72% of pediatric ALL patients were classified as high risk, while 28% were classified as standard risk (Figure 2). A predominance of high-risk patients was also observed at the hospital level, with high-risk proportions of 52% at RSHS, 64% at RSCM, and 64% at Dharmais Hospital. Estimated annual number of pediatric acute lymphoblastic leukemia (ALL) patients in Indonesia used in the forecasting model. Distribution of pediatric acute lymphoblastic leukemia patients by risk group. Among standard-risk patients, induction therapy represented the largest treatment phase at the national level, accounting for 54% of patients, followed by consolidation (30%) and maintenance (16%). These national treatment-phase proportions represent inputs applied in the national forecasting model and are not weighted averages of the corresponding treatment-phase percentages across the three participating hospitals. Hospital-level distributions showed similar patterns, with induction therapy ranging from 47% at RSCM to 54% at Dharmais Hospital, while maintenance therapy accounted for a smaller proportion, ranging from 6% to 16% across hospitals. For high-risk patients, induction therapy also accounted for the largest proportion of treatment phases (47% nationally), followed by consolidation (26%), re-induction (14%), and maintenance (14%). At the hospital level, the proportion of high-risk patients receiving induction therapy ranged from 34% at RSHS to 47% at Dharmais Hospital, while re-induction therapy ranged from 14% to 30% across hospitals (Table 1). Estimated Drug Requirements per Treatment Course For standard-risk pediatric ALL patients, induction therapy required the highest quantities of injectable medicines per treatment course. Specifically, induction therapy required 36 mg of intrathecal methotrexate, 7.2 mg of vincristine, 40 mg of daunorubicin, 36,000 IU of L-asparaginase, 840 mg of prednisone, and 3 mg of dexamethasone. During consolidation therapy, the main drug requirements included 2,400 mg of high-dose methotrexate and 1,400 mg of 6-mercaptopurine, while maintenance therapy involved prolonged use of oral agents, particularly 18,480 mg of 6-mercaptopurine, 1,056 mg of oral methotrexate, and 537.6 mg of oral dexamethasone, alongside intermittent injectable chemotherapy (Supplementary Table S1). For high-risk patients, drug requirements per treatment course were substantially higher and more complex across all treatment phases. Induction therapy required 48,000 IU of L-asparaginase, 80 mg of daunorubicin, 7.2 mg of vincristine, and 156.8 mg of oral dexamethasone, in addition to 36 mg of intrathecal methotrexate. Consolidation therapy included 2,400 mg of high-dose methotrexate, 1,400 mg of 6-mercaptopurine, and 1,600 mg of cyclophosphamide. Re-induction therapy introduced additional cytotoxic demand, including 360 mg of cytarabine, 40 mg of daunorubicin, and 134.4 mg of oral dexamethasone. Maintenance therapy for high-risk patients required sustained oral chemotherapy, notably 18,200 mg of 6-mercaptopurine, 1,040 mg of oral methotrexate, and 627.2 mg of oral dexamethasone, together with 33.6 mg of vincristine and 96 mg of intrathecal methotrexate (Supplementary Table S2). Drug Prices Applied in the Analysis Unit prices for pediatric ALL medicines varied across drug classes but were generally consistent across hospitals and at the national level. Among injectable chemotherapy agents, l-asparaginase had the highest unit price, at IDR 1,370,000 per pack across all hospitals and nationally. Other injectable agents showed lower unit prices, including cytarabine, which ranged from IDR 599,400 to IDR 612,670 per pack, and daunorubicin, which was uniformly priced at IDR 300,000 per pack. Vincristine prices ranged from IDR 92,876 to IDR 97,125 per pack at the hospital level, with a national reference price of IDR 87,200 per pack (Supplementary Table S3). USD equivalents of the principal expenditure estimates are reported in the national budget results to facilitate international interpretation. When standardized according to medicine-specific dosing units, unit prices varied across drug classes and procurement settings. Other injectable agents showed moderate variation, with cytarabine priced between IDR 5,994 and IDR 6,127 per mg, daunorubicin at IDR 15,000 per mg, and vincristine ranging from IDR 92,876 to IDR 97,125 per mg. Oral chemotherapy agents were substantially less expensive on a per-milligram basis, including 6-mercaptopurine at IDR 47 per mg, oral methotrexate at IDR 476 per mg, and prednisone ranging from IDR 14 to IDR 28 per mg across hospitals and nationally (Supplementary Table S4). National Pharmaceutical Requirements and Budget Estimates At the national level, pharmaceutical requirements and budget implications differed substantially between standard-risk and high-risk pediatric ALL patients (Table 2 and Table 3). The total estimated annual national pharmaceutical expenditure was IDR 1.43 billion (USD 95,257) for standard-risk patients and IDR 4.88 billion (USD 298,129) for high-risk patients, corresponding to a combined annual budget of approximately IDR 5.91 billion (USD 393,386) across both risk groups. For standard-risk patients, l-asparaginase represented the largest single pharmaceutical requirement, with an estimated national demand of 580–870 packs per year, corresponding to a total budget of approximately IDR 993.3 million. Other injectable agents contributed smaller but notable shares of total expenditure, including vincristine, with an estimated national demand of 2,407–2,804 packs and a total cost of IDR 227.2 million, and daunorubicin, with a fixed national requirement of 290 packs and an associated cost of IDR 87.0 million. Oral chemotherapy agents accounted for lower overall costs, including 6-mercaptopurine (183–228 packs; IDR 48.7 million) and oral methotrexate (607–663 packs; IDR 22.7 million). Table 2Estimated National Pharmaceutical Requirements and Budget Implications for Standard-Risk Pediatric Acute Lymphoblastic Leukemia Patients in IndonesiaDrugRSHSRSCMRS DharmaisNationalQuantityBudget (IDR)QuantityBudget (IDR)QuantityBudget (IDR)QuantityBudget (IDR)L-Asparaginase64-96109,600,00064-96109,600,00084-126143,850,000580-870993,250,000Vincristine215-33626,757,938186-28822,515,000342-54040,958,3162,407–2,804227,199,600Daunorubicin32-329,600,00032-329,600,00042-4212,600,000290-29087,000,0006-Mercaptopurine17-204,382,65013-163,435,05027-337,107,000183-22848,682,950Methotrexate IT74-1173,581,25072-1123,496,00090-1474,147,500624-1,02228,805,000Methotrexate PO43-471,606,50029-311,071,00085-933,177,300607-66322,669,500HD Methotrexate45-452,700,00048-482,880,00036-362,160,000243-24314,580,000Dexamethasone PO33-36196,65022-24121,90065-71231,200463-5064,845,000Prednisone27-27278,10027-27186,30036-36248,400244-2443,416,000Dexamethasone3-3299,7003-3299,7003-3299,7004-12877,600Notes: Costs are presented primarily in Indonesian Rupiah (IDR). The total national standard-risk pharmaceutical expenditure of IDR 1,431,325,650 corresponds to approximately USD 95,257, using the reference-period exchange rate of IDR 15,026 per USD 1. Estimated National Pharmaceutical Requirements and Budget Implications for Standard-Risk Pediatric Acute Lymphoblastic Leukemia Patients in Indonesia Notes: Costs are presented primarily in Indonesian Rupiah (IDR). The total national standard-risk pharmaceutical expenditure of IDR 1,431,325,650 corresponds to approximately USD 95,257, using the reference-period exchange rate of IDR 15,026 per USD 1. Table 3Estimated National Pharmaceutical Requirements and Budget Implications for High-Risk Pediatric Acute Lymphoblastic Leukemia Patients in IndonesiaDrugRSHSRSCMRS DharmaisNationalQuantityBudget (IDR)QuantityBudget (IDR)QuantityBudget (IDR)QuantityBudget (IDR)L-Asparaginase60-96106,860,00035-5662,335,00050-8089,050,0001,620–2,5922,885,220,000Vincristine197-30024,135,563102-15612,255,000191-30022,801,0586,181–9,708692,760,400Daunorubicin70-7021,000,00036-3610,800,00046-4613,800,0001,490–1,490447,000,0006-Mercaptopurine44-6613,029,50016-244,738,00012-183,553,500388-582114,896,500Cyclophosphamide48-484,954,41652-523,463,20040-403,864,400152-22821,790,340HD Methotrexate12-15810,0006-8420,00013-17900,000405-50527,300,000Methotrexate IT48-481,800,00028-281,064,00024-24840,000720-72025,200,000Methotrexate PO67-1103,159,45036-581,677,90047-782,231,2501,493–2,48270,953,750Dexamethasone PO28-31168,15014-1679,50042-46149,6001,346–1,47214,090,000Prednisone36-36370,80021-21144,90018-18124,200540-5407,560,000Cytarabine44-6633,550,00028-4221,350,00024-3617,982,000280-280171,547,600Dexamethasone3-3299,7003-3299,7003-3299,7007-181,371,250Notes: Costs are presented primarily in Indonesian Rupiah (IDR). The total national high-risk pharmaceutical expenditure of IDR 4,479,689,840 corresponds to approximately USD 298,129, using the reference-period exchange rate of IDR 15,026 per USD 1. Estimated National Pharmaceutical Requirements and Budget Implications for High-Risk Pediatric Acute Lymphoblastic Leukemia Patients in Indonesia Notes: Costs are presented primarily in Indonesian Rupiah (IDR). The total national high-risk pharmaceutical expenditure of IDR 4,479,689,840 corresponds to approximately USD 298,129, using the reference-period exchange rate of IDR 15,026 per USD 1. For high-risk patients, national pharmaceutical requirements and budget implications were markedly higher. L-asparaginase again dominated national demand, with an estimated requirement of 1,620–2,592 packs per year, corresponding to a total cost of IDR 2,885.2 million. National demand for vincristine increased substantially to 6,181–9,708 packs, with a total cost of IDR 692.8 million, while daunorubicin requirements rose to 1,490 packs, corresponding to IDR 447.0 million. Additional cytotoxic agents not used in standard-risk regimens contributed to overall expenditure, including cyclophosphamide (152–228 packs; IDR 171.5 million) and cytarabine (280 packs; IDR 32.1 million). Oral agents continued to contribute consistently to total pharmaceutical requirements, with 6-mercaptopurine requiring 388–582 packs (IDR 114.9 million) and oral methotrexate requiring 1,493–2,482 packs (IDR 71 million). Cost Distribution by Treatment Phase Average pharmaceutical costs per patient varied substantially by treatment phase and risk group (Supplementary Table S5). For standard-risk pediatric ALL patients, induction therapy was associated with the highest average cost per patient at the national level, estimated at IDR 8,435,707 per patient, followed by maintenance therapy (IDR 5,202,370 per patient) and consolidation therapy (IDR 346,251 per patient). Hospital-level average costs per patient showed modest variation, which may reflect differences in projected patient distribution across treatment phases, local unit prices, and rounding assumptions within the forecasting model rather than differences in dosing protocols. For standard-risk patients, induction-phase average costs ranged from IDR 8.49 million at Dharmais Hospital to IDR 11.18 million at RSCM, while maintenance-phase costs ranged from IDR 5.39 million to IDR 5.63 million across hospitals. For high-risk patients, induction therapy also represented the most costly treatment phase, with a national average cost of IDR 11,100,009 per patient. This was followed by maintenance therapy (IDR 5,756,574 per patient), re-induction therapy (IDR 4,051,568 per patient), and consolidation therapy (IDR 805,525 per patient). At the hospital level, induction costs for high-risk patients ranged from IDR 6.17 million at RSCM to IDR 11.20 million at RSHS, while re-induction costs were relatively consistent across hospitals, ranging from IDR 4.00 million to IDR 4.07 million per patient. A similar pattern was observed across hospitals, with limited variation in phase-specific average costs. Concentration of Pharmaceutical Expenditure Pharmaceutical expenditure for pediatric ALL treatment was highly concentrated among a limited number of medicines (Table 4). At the national level, the ten highest-cost drug–risk group combinations accounted for approximately 97.08% of total estimated pharmaceutical expenditure across both risk groups. L-asparaginase was the dominant cost driver, accounting for 48.81% of total national pharmaceutical spending among high-risk patients, corresponding to IDR 2.89 billion, and an additional 16.80% among standard-risk patients, corresponding to IDR 993.3 million. Combined, l-asparaginase represented approximately 65.61% of all projected pharmaceutical expenditure. Table 4Concentration of Pharmaceutical Expenditure by Drug for Pediatric Acute Lymphoblastic Leukemia TreatmentRankDrugRisk GroupNational Cost (IDR)Share of Total SpendingCumulative Share1L-AsparaginaseHigh Risk2,885,220,00048.81%48.81%2L-AsparaginaseStandard Risk993,250,00016.80%65.61%3VincristineHigh Risk692,760,40011.72%77.33%4DaunorubicinHigh Risk447,000,0007.56%84.90%56-MercaptopurineHigh Risk227,199,6003.84%88.74%6VincristineStandard Risk171,547,6002.90%91.64%7CyclophosphamideHigh Risk114,896,5001.94%93.59%8HD MethotrexateHigh Risk87,000,0001.47%95.06%9DaunorubicinStandard Risk70,953,7501.20%96.26%10Methotrexate ITHigh Risk48,682,9500.82%97.08%11Methotrexate POHigh Risk28,805,0000.49%97.57%12Dexamethasone POHigh Risk27,300,0000.46%98.03%136-MercaptopurineStandard Risk25,200,0000.43%98.46%14CytarabineHigh Risk22,669,5000.38%98.84%15PrednisoneHigh Risk21,790,3400.37%99.21%16Methotrexate ITStandard Risk14,580,0000.25%99.46%17Methotrexate POStandard Risk14,090,0000.24%99.69%18HD MethotrexateStandard Risk7,560,0000.13%99.82%19Dexamethasone POStandard Risk4,845,0000.08%99.90%20PrednisoneStandard Risk3,416,0000.06%99.96%21DexamethasoneHigh Risk1,371,2500.02%99.99%22DexamethasoneStandard Risk877,6000.01%100.00%Notes: The ten highest-cost drug–risk group combinations accounted for approximately 95.06% of total estimated national pharmaceutical expenditure. Costs are presented primarily in IDR; the combined national pharmaceutical expenditure of IDR 5,911,015,490 corresponds to approximately USD 393,386 using the reference-period exchange rate of IDR 15,026 per USD 1. Concentration of Pharmaceutical Expenditure by Drug for Pediatric Acute Lymphoblastic Leukemia Treatment Notes: The ten highest-cost drug–risk group combinations accounted for approximately 95.06% of total estimated national pharmaceutical expenditure. Costs are presented primarily in IDR; the combined national pharmaceutical expenditure of IDR 5,911,015,490 corresponds to approximately USD 393,386 using the reference-period exchange rate of IDR 15,026 per USD 1. Among high-risk patients, other major contributors to national pharmaceutical expenditure included vincristine (11.72%; IDR 692.8 million), daunorubicin (7.56%; IDR 447.0 million and cytarabine (2.90%; IDR 171.5 million). High-risk 6-mercaptopurine contributed 1.94% (IDR 114.9 million) of total national pharmaceutical expenditure. For standard-risk patients, expenditure was also concentrated in a limited number of medicines. After l-asparaginase, the largest contributors were vincristine (3.84%; IDR 227.2 million) and daunorubicin (1.47%; IDR 87.0 million). The remaining medicines each accounted for less than 1% of total national pharmaceutical expenditure individually. These findings indicate that national budget requirements for pediatric ALL are driven primarily by a small number of essential injectable chemotherapy agents. Sensitivity and Scenario Analysis The base-case estimated national pharmaceutical budget was IDR 5.91 billion (approximately USD 393,386). In the deterministic one-way sensitivity analysis, a 20% reduction in either the national pediatric ALL caseload or medicine prices decreased the estimated national budget to IDR 4.73 billion (USD 314,709), whereas a 20% increase increased the budget to IDR 7.09 billion (USD 472,063). Under the alternative treatment-completion scenario, reducing complete-course treatment delivery from 100% to 80% decreased the estimated pharmaceutical budget from IDR 5.91 billion (USD 393,386) to IDR 4.73 billion (USD 314,709). This scenario represents the effect of incomplete treatment delivery relative to the idealized complete-course procurement requirement and does not represent an observed treatment-completion rate in Indonesia (Supplementary Table S6; Figure 3). Deterministic one-way sensitivity and treatment-completion scenario analysis of the estimated national pharmaceutical budget. Discussion This study provides the first national, morbidity-based estimation of pharmaceutical requirements and budget implications for pediatric ALL in Indonesia. Using registry data, hospital treatment patterns, national clinical guidelines, and procurement prices, the analysis shows that pediatric ALL represents a substantial and sustained pharmaceutical demand, with an estimated 957 patients treated annually, of whom the majority are classified as high risk. Pharmaceutical requirements and expenditure were highly concentrated in a limited number of injectable chemotherapy agents, particularly l-asparaginase, which consistently emerged as the dominant cost driver at both hospital and national levels. Across risk groups, induction therapy accounted for the highest pharmaceutical costs per patient, reflecting the intensity and front-loaded nature of ALL treatment protocols, while high-risk patients contributed disproportionately to national pharmaceutical expenditure due to more intensive regimens and additional treatment phases. Overall, these findings suggest that, under the assumptions applied in the forecasting model, estimated national pharmaceutical needs for pediatric ALL are primarily driven by treatment intensity and risk distribution, underscoring the value of risk-stratified, regimen-specific forecasting approaches for procurement planning in resource-limited settings. These estimates should be interpreted as model-based procurement-planning estimates rather than precise predictions of observed medicine consumption, as their magnitude remains dependent on the epidemiological, treatment-distribution, dosing, completion, and pricing assumptions incorporated into the model. The dominance of l-asparaginase as the primary cost driver observed in this study reflects its central role in pediatric ALL treatment protocols, which require repeated administration of injectable formulations using weight- or body surface area–based dosing, resulting in high cumulative drug consumption and procurement costs. Similar patterns have been reported in international pediatric oncology analyses, where asparaginase consistently accounts for a substantial share of chemotherapy expenditure, particularly in LMICs where alternative formulations and negotiated pricing may be limited.19 The finding that induction therapy represents the most costly treatment phase per patient across both risk groups is consistent with the front-loaded intensity of ALL treatment, during which multiple injectable cytotoxic agents, including anthracyclines, vinca alkaloids, corticosteroids, and asparaginase, are administered over a short period at relatively high doses, a structure well documented in contemporary ALL protocols. Higher pharmaceutical requirements among high-risk patients are also expected, as these regimens involve additional treatment phases such as re-induction and greater cumulative exposure to cytotoxic agents, leading to increased overall drug consumption; this pattern has been similarly reported in pediatric ALL cost and treatment-intensity analyses from LMIC settings.29,30 Importantly, the concentration of pharmaceutical expenditure in a limited number of medicines identified in this study reflects protocol-driven treatment needs rather than inefficiencies in prescribing or procurement, underscoring the importance of prioritizing accurate forecasting and reliable supply of a small set of essential chemotherapy agents within national procurement systems.31 The overall patterns observed in this study are broadly consistent with findings from pediatric ALL programs in other LMICs, where pharmaceutical requirements and treatment costs are similarly driven by regimen intensity and the use of a limited number of essential injectable chemotherapy agents. Studies from Asia, Latin America, and Africa have reported that asparaginase, anthracyclines, and vinca alkaloids account for a substantial proportion of chemotherapy consumption and expenditure in pediatric ALL, reflecting common protocol structures across settings rather than country-specific prescribing practices.32,33 The predominance of induction-phase costs observed in this analysis has also been documented in multicenter pediatric oncology costing studies, which show that early treatment phases consume a disproportionate share of total chemotherapy resources due to intensive drug combinations and higher dosing frequency.34 While absolute cost levels vary across countries because of differences in procurement mechanisms, pricing policies, and market availability, the concentration of expenditure in a small number of essential medicines is a recurring feature of pediatric ALL treatment globally, including in settings with centralized procurement systems.35 These similarities suggest that the pharmaceutical demand patterns identified in Indonesia are consistent with international experience and support the potential applicability of morbidity-based forecasting approaches for pediatric oncology medicines in comparable health system contexts. The variation in risk-group distribution across hospitals, particularly the more balanced profile observed at RSHS compared with the higher proportion of high-risk patients at RSCM and Dharmais, may reflect differences in referral pathways, catchment populations, timing of diagnosis, and case-mix complexity across national referral centers. This inter-hospital heterogeneity has direct implications for national extrapolation because pharmaceutical requirements differ substantially between standard-risk and high-risk regimens. Consequently, national estimates derived from referral-center distributions may be sensitive to the risk-group composition used in the forecasting model and may not fully represent the case mix of pediatric ALL patients treated across all Indonesian facilities. The national estimates should therefore be interpreted as model-based procurement requirements informed by referral-hospital patterns rather than as directly observed national utilization. The findings of this study have important implications for pharmaceutical planning and procurement for pediatric oncology care, particularly in settings where treatment programs rely on centralized purchasing and limited fiscal space. By demonstrating that national pharmaceutical demand for pediatric ALL is driven by a small number of essential injectable medicines and concentrated in specific treatment phases, this analysis highlights the value of morbidity-based forecasting as a practical tool to support evidence-based procurement planning in contexts where consumption data may underestimate true need due to access constraints or stock interruptions.10 Operationally, the model can translate projected patient numbers and risk-group distributions into medicine-specific quantities and budget requirements, enabling procurement managers to anticipate high-budget medicines and prioritize them during purchasing and inventory planning. The identification of l-asparaginase, vincristine, daunorubicin, and cytarabine as dominant contributors to national drug requirements suggests that procurement strategies prioritizing these medicines, through improved forecasting accuracy, supplier diversification, and supply continuity, may be particularly important for ensuring uninterrupted pediatric ALL treatment.36 In the Indonesian context, these findings are especially relevant because pediatric oncology services are delivered within the framework of the JKN, and national clinical guidelines. As such, accurate estimates of pharmaceutical requirements can support evidence-based benefit package planning, reimbursement decisions, and alignment between treatment protocols and medicine financing.37 By identifying the medicines and treatment phases that account for the greatest share of national expenditure, this forecasting approach may also help policymakers anticipate budget needs, strengthen procurement strategies, and improve continuity of access to essential pediatric oncology medicines under JKN. Periodic application of the model using updated patient, treatment-pattern, and procurement-price data could further support prospective budget planning and alignment between treatment recommendations, medicine procurement, and financing under JKN. Furthermore, the marked differences in pharmaceutical requirements between standard-risk and high-risk patients underscore the importance of incorporating risk stratification and regimen structure into national quantification exercises, rather than relying on aggregate or historical utilization data alone.38 Ultimately, these findings suggest that structured, regimen-specific forecasting can strengthen alignment between clinical guidelines, procurement decisions, and budget allocation for pediatric cancer care without requiring complex economic modeling. The sensitivity analysis further demonstrates that the projected pharmaceutical budget is strongly dependent on the size of the treated population, medicine prices, and patient-size assumptions used for BSA-based dosing.39 Variation of ±20% in the national caseload or medicine prices produced proportional changes in the total estimated budget. These findings underscore the importance of regularly updating epidemiological inputs, and procurement prices when the forecasting model is used for planning.40 For decision-makers, this indicates that procurement forecasts should be periodically recalibrated as caseload and medicine prices change, rather than treated as fixed annual estimates. The treatment-completion scenario also illustrates the distinction between theoretical procurement requirements and realized medicine use: an 80% treatment-course delivery scenario reduced the estimated budget by approximately 20% compared with the idealized 100% complete-course base case. This study has some important strengths, most notably that it is, to our knowledge, the first national study to apply a morbidity-based forecasting approach to estimate pharmaceutical requirements and budget implications for pediatric ALL in Indonesia, thereby generating novel and decision-relevant evidence for pediatric oncology procurement planning. The analysis integrates multiple data sources, including national registry information, hospital treatment patterns, standardized clinical guidelines, and official procurement prices, enabling regimen- and risk-specific estimation of drug needs that reflect routine clinical practice. At the same time, several limitations should be acknowledged. Drug requirements were estimated using average body weight and body surface area assumptions and assumed full completion of treatment regimens without dose modifications, treatment interruptions, or drug wastage. Furthermore, the reference BSA of 0.8 m2 was selected based on hospital-derived patient characteristics and clinical input from pediatricians at the participating centers. Although this value was considered clinically reasonable for the modeled pediatric population, BSA varies substantially with age and body size; therefore, use of a single reference value may not capture the full anthropometric variability of Indonesian children with ALL. Although uncertainty in selected model parameters and treatment completion was explored through deterministic sensitivity and scenario analyses, these scenarios were based on predefined analytical ranges rather than patient-level empirical distributions. Therefore, they should be interpreted as assessments of model sensitivity rather than estimates of observed clinical variability. In addition, the analysis was based on data from three national referral hospitals and may not fully capture variability in treatment practices across all facilities, although these centers represent the main providers of pediatric oncology care nationally. Finally, procurement prices reflect values listed in the national electronic catalogue at a single point in time and do not account for potential price fluctuations or supplier-specific agreements. Conclusion This study provides a national morbidity-based estimation of pharmaceutical requirements and budget implications for pediatric ALL in Indonesia. By integrating registry data, hospital treatment patterns, national clinical guidelines, and procurement prices, the analysis offers a structured and transparent overview of drug needs across treatment phases and risk groups. The findings suggests that the estimated national pharmaceutical demand for pediatric ALL is driven primarily by treatment intensity and risk distribution, with a limited number of essential injectable medicines accounting for the majority of drug requirements and expenditure. These results highlight the potential value of morbidity-based, regimen-specific forecasting as a practical tool to support pharmaceutical procurement planning in pediatric oncology, particularly in resource-limited settings where consumption data may underestimate true need. However, these estimates represent theoretical procurement requirements rather than observed national medicine consumption and should be interpreted in light of the model assumptions and the use of referral-hospital data and time-specific procurement prices. By identifying key cost drivers and phases of treatment with the greatest budget impact, this study provides evidence that can inform more aligned planning between clinical guidelines, procurement decisions, and budget allocation. The framework presented may also serve as a foundation for future refinement and extension to other pediatric cancers and priority diseases as more granular data become available, with future iterations prioritizing expanded sensitivity analyses using empirically derived parameter ranges to further assess uncertainty in pharmaceutical requirements and budget estimates. Data Sharing Statement The data and materials in the study are available from the corresponding author upon reasonable request. Ethical Approval The present study involved a secondary, non-interventional analysis of previously collected data and did not involve new participant recruitment, intervention, or additional collection of identifiable patient information. The underlying database had received ethical approval and was established with informed consent. No separate ethical approval was obtained for the present secondary analysis. The analysis was conducted using existing data for pharmaceutical forecasting and procurement-planning purposes. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement The data and materials in the study are available from the corresponding author upon reasonable request.